Septerna (SEPN) to Release Quarterly Earnings on Wednesday

Septerna (NASDAQ:SEPN) is anticipated to post its Q3 2025 results before the market opens on Wednesday, November 19th. Analysts expect Septerna to post earnings of $0.19 per share and revenue of $75.00 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The firm had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative return on equity of 17.86% and a negative net margin of 266.77%. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Septerna Price Performance

NASDAQ SEPN opened at $19.24 on Wednesday. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The firm has a market capitalization of $857.72 million and a P/E ratio of -12.74. The business’s 50-day simple moving average is $18.96 and its 200-day simple moving average is $13.57.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its holdings in shares of Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares during the last quarter. Rhumbline Advisers increased its position in Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares during the period. Geode Capital Management LLC raised its stake in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after acquiring an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the period. Finally, CW Advisors LLC acquired a new position in Septerna during the 2nd quarter worth $133,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SEPN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Septerna in a research note on Friday, September 5th. Wall Street Zen lowered Septerna from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright raised their target price on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Septerna has an average rating of “Moderate Buy” and a consensus price target of $27.75.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.